Conflicts of Interest in Drug Research

Publisher Website
Google Scholar
Abstract
To the Editor: The recent flood of articles and letters in the Journal on the relation between endometrial carcinoma and the use of estrogens serves to emphasize a serious ethical problem in medicine today. Two recent articles on this subject reached contradictory conclusions. A study by Antunes et al.,1 supported by the National Cancer Institute, confirmed previous reports of a markedly increased risk of this tumor in persons taking estrogens. The article by Horwitz and Feinstein,2 partially supported by funds from Ayerst Laboratories (manufacturers of Premarin, the most widely promoted conjugated estrogen), suggested that this increased risk may have been . . .

This publication has 2 references indexed in Scilit: